French-Austrian lab reports positive results from new Covid vaccine trials

Vaccine against Covid-19
The vaccine is made using an 'inactivated' version of the coronavirus. Photo: Odd Andersen/AFP
The French-Austrian lab Valneva said that its trial showed "positive" results for its vaccine against Covid-19, but has no guarantees it will be able to sell its jab.

The French government has said that the European Union was still in negotiations to buy the vaccine, after the UK government terminated its own supply deal last month, which is so far the only order for Valneva.

Valvena said its Phase 3 trial, conducted among 4,012 adults in Britain, showed “positive” results for the vaccine, providing more neutralizing antibodies than the shot made by British pharmaceutical giant AstraZeneca.

(article continues below)

See also on The Local:

Valneva’s VLA2001 vaccine is based on an “inactivated” version of the coronavirus itself to ward off Covid-19.

“This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America,” said Adam Finn, professor of paediatrics at University of Bristol and the chief investigator.

“These results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic,” Finn said in a company statement.

Valneva’s shares soared by more than 30 percent following the announcement. They had sunk after Britain cancelled its contract last month.

The company said it has begun the vaccine approval process with the UK’s health regulator and is preparing to submit a request with the European Medicines Agency.

“We are committed to bringing our differentiated vaccine candidate to licensure as quickly as possible and continue to believe that we will be able to make an important contribution to the global fight against the Covid-19 pandemic,” said Valneva CEO Thomas Lingelbach.

Member comments

    1. Where did you get that from. The UK has cancelled the supply agreement (no doubt for non supply!) that is not the same as authorising it for use.

Become a Member to leave a comment.Or login here.